SCHEMBL10211596

SCHEMBL10211596

COC(=O)c1ccc2nc(-c3ccc(C(F)(F)F)cc3)c(=O)[nH]c2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.62
ALDH1A1 P00352 2/20 0.62
LMNA P02545 2/20 0.62
HTT P42858 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
CHEK2 O96017 4/20 0.50
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
MMP13 P45452 1/20 0.47
ATM Q13315 1/20 0.44
PARP1 P09874 3/20 0.44
BRD4 O60885 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
RHEB Q15382 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ATR Q13535 1/20 0.43
NPC1 O15118 1/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9954617 0.87 KDM4E (0.56) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL19982668 0.85 CHEK2 (0.67) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL10211619 0.85 SIRT2 (0.56) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL1458088 0.85 KDM4E (0.56) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL6304842 0.81 KDM4E (0.70) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL10210066 0.80 KDM4E (0.53) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL15665808 0.78 ALDH1A1 (0.56) KDM4EALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL17184393 0.78 BRD4 (0.56) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL22963739 0.78 HTT (0.65) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL29396650 0.78 HTT (0.65) KDM4EALDH1A1LMNAHTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661428-B1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2017-06-07 EP disclosed
US-20130303517-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME LLC 2013-11-14 US disclosed
WO-2012087861-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303517-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS HRH2, NPY2R, CNKSR1 KDM4E 1506/4885ALDH1A1 1713/4885LMNA 3865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.